Safety Study of Triple Drug Co-Administration in Zanzibar
Author Information
Author(s): Mohammed Khalfan A., Haji Hamad J., Gabrielli Albis-Francesco, Mubila Likezo, Biswas Gautam, Chitsulo Lester, Bradley Mark H., Engels Dirk, Savioli Lorenzo, Molyneux David H.
Primary Institution: Programme for Lymphatic Filariasis, Schistosomiasis and Soil-Transmitted Helminthiasis, Ministry of Health and Social Welfare, Zanzibar, United Republic of Tanzania
Hypothesis
Is the co-administration of ivermectin, albendazole, and praziquantel safe for individuals in areas endemic for lymphatic filariasis, soil-transmitted helminthiasis, and schistosomiasis?
Conclusion
The study found that co-administration of the three drugs is safe and results in only mild, self-limiting side effects.
Supporting Evidence
- Side effects reported were mild and self-limiting.
- 10% of participants reported side effects during the pilot intervention, while only 1.4% reported during the nationwide intervention.
- Most side effects occurred within 24 hours and subsided quickly.
Takeaway
Giving three medicines together to treat worm infections in Zanzibar is safe and doesn't cause serious problems.
Methodology
The study involved co-administering ivermectin, albendazole, and praziquantel to a pilot group of 5,055 individuals, followed by a country-wide intervention targeting about 700,000 individuals, with active and passive surveillance for side effects.
Limitations
The study did not assess individual parasitological status, limiting the ability to correlate infection levels with side effects.
Participant Demographics
Participants included both children and adults from two endemic sites in Zanzibar, with a higher number of females than males.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website